Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 15, 2024.

A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia.

Here are the top 5 biosimilar articles for the week of January 8, 2024.

A recent study found that the COVID-19 pandemic had little impact on the knowledge and attitudes of German and Swiss pharmacists regarding biologics and biosimilars between 2020 and 2022.

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Adults with inflammatory diseases maintained disease control when transitioning from originator adalimumab (Humira) to biosimilar SB5 in a pan-European study.

Here are the top 5 biosimilar articles for 2023.

Here are the top 5 biosimilar articles for the week of December 18th, 2023.

Comprehensive assay research concluded similar structures, functions, and stability between reference adalimumab (Humira) and adalimumab-aqvh.

Here are the top 5 biosimilar articles for the week of December 11, 2023.

A national study on patients with rheumatoid arthritis (RA) compares the disease activity and drug survival rate between an etanercept biosimilar and the originator (Enbrel).

Here are the top 5 biosimilar articles for the week of December 4, 2023.

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

Here are the top 5 biosimilar articles for the week of November 27, 2023.

Here are the top 5 biosimilar articles for the week of November 20, 2023.

A China-based study where data were collected from patients with inflammatory bowel disease (IBD) showed safety and efficacy of the adalimumab biosimilar HS016.